Journal Article

Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial

Kate, Vikram, Ganesh, Rajesh Nachiappa, Dubashi, Biswajit, Kayal, Smita, Penumadu, Prasanth, Nisha, Yadav, L, Charles, V.C., Sunitha, Jafa, Esha, Ganesan, Prasanth

2023

Overview

Purpose The role of aspirin in cancer prevention has been well defined; the last decade revealed its therapeutic role with improved efficacy when aspirin was added to capecitabine in heavily pre-treated metastatic colorectal cancer. Aspirin affects tumour growth through the PI3K pathway, which regulates apoptosis and autophagy. The objective was to compare the efficacy of aspirin plus epirubicin, oxaliplatin, capecitabine (EOX) chemotherapy versus EOX alone in locally advanced and metastatic gastric cancer. Methods All patients with advanced gastric cancer reporting to the Department of Medical oncology between March 2017 and May 2019 were screened for study eligibility. They were randomly assigned to standard EOX with or without aspirin at a daily dose of 150 mg. Tumour measurements were assessed at baseline and after 3–4 cycles by an independent blinded radiologist according to RECIST criteria 1.1. Toxicity profiles were recorded as per CTCAE v 4.03. Per-protocol group was identified as 70 patients. The primary endpoint was overall response rates in the per-protocol group (defined as patients who received a minimum of 3 cycles and had an evaluable response after randomization). The secondary endpoints included toxicity analysis, progression-free survival, and overall survival. Results Ninety-five patients who fulfilled the study inclusion and exclusion criteria were randomized to group 1 EOX (50) or group 2 EOX plus aspirin (45). Seventy patients were included for the per-protocol analysis. The overall response rate in group 1 was 27% compared to group 2, which was 42%, P  = 0.176. The median duration of follow was 29 (18.56–39.45) months. The median overall survival ( n  = 95) of group 1 versus group 2 was 11 (8.58–13.42) months and 10 (6.86–13.14) months, respectively, P  = 0.90. There was no statistical significance in the overall survival per-protocol analysis ( n  = 70) between group one 12 (8.75–15.25) months versus group two 12 (6.21–17.79) months, P  = 0.50. Conclusions There was no improvement in the response rates, progression-free survival, and overall survival on adding aspirin to EOX chemotherapy in locally advanced and metastatic gastric cancer in an unselected population. A further role of PI3K mutation as a biomarker needs to be evaluated in this setting.

• Publisher: Springer US,Springer Nature B.V
• Subject: Cancer Research / Gastroenterology / Internal Medicine / Medicine / Medicine & Public Health / Oncology / Original Research / Radiotherapy